+

WO2007039458A3 - Conjugues peptidiques du vih et leurs utilisations - Google Patents

Conjugues peptidiques du vih et leurs utilisations Download PDF

Info

Publication number
WO2007039458A3
WO2007039458A3 PCT/EP2006/066526 EP2006066526W WO2007039458A3 WO 2007039458 A3 WO2007039458 A3 WO 2007039458A3 EP 2006066526 W EP2006066526 W EP 2006066526W WO 2007039458 A3 WO2007039458 A3 WO 2007039458A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
compositions
peptide conjugates
hiv peptide
composition
Prior art date
Application number
PCT/EP2006/066526
Other languages
English (en)
Other versions
WO2007039458A2 (fr
Inventor
Martin Bachmann
Philippe Saudan
Andrea Jegerlehner
Till Alexander Roehn
Gary Jennings
Original Assignee
Cytos Biotechnology Ag
Martin Bachmann
Philippe Saudan
Andrea Jegerlehner
Till Alexander Roehn
Gary Jennings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology Ag, Martin Bachmann, Philippe Saudan, Andrea Jegerlehner, Till Alexander Roehn, Gary Jennings filed Critical Cytos Biotechnology Ag
Publication of WO2007039458A2 publication Critical patent/WO2007039458A2/fr
Publication of WO2007039458A3 publication Critical patent/WO2007039458A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18123—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne les domaines de la médecine, de la santé publique, de l'immunologie, de la biologie moléculaire et de la virologie. L'invention porte sur une composition comprenant une pseudo-particule virale (VLP) liée à au moins un antigène, l'antigène étant le peptide gp160 du VIH. Cette invention concerne également un procédé de production de la composition. Les compositions de cette invention sont utiles dans la production de vaccins utiles, en particulier, dans la prévention et le traitement de maladies. Ces compositions induisent, de plus, des réponses immunes efficientes, notamment des réponses anticorps.
PCT/EP2006/066526 2005-09-21 2006-09-20 Conjugues peptidiques du vih et leurs utilisations WO2007039458A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05108697.3 2005-09-21
EP05108697 2005-09-21

Publications (2)

Publication Number Publication Date
WO2007039458A2 WO2007039458A2 (fr) 2007-04-12
WO2007039458A3 true WO2007039458A3 (fr) 2007-06-07

Family

ID=37499997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/066526 WO2007039458A2 (fr) 2005-09-21 2006-09-20 Conjugues peptidiques du vih et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2007039458A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009011912A1 (fr) * 2007-07-18 2009-01-22 Bristol-Myers Squibb Company Composition de traitement du vih comprenant des particules apparentées au virus
CA2863658C (fr) * 2012-02-03 2023-03-14 Emory University Compositions immunostimulatrices, particules et applications associees
WO2017173334A1 (fr) * 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Administration de médicament médiée par un récepteur fc
EP3752194A4 (fr) 2018-02-13 2022-03-16 Checkmate Pharmaceuticals, Inc. Compositions et méthodes d'immunothérapie anti-tumorale
KR20210006905A (ko) 2018-04-09 2021-01-19 체크메이트 파마슈티칼스 바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007616A1 (fr) * 1986-06-12 1987-12-17 Biogen N.V. Peptides impliques dans la pathogenese d'une infection du type hiv
EP0330359A2 (fr) * 1988-02-25 1989-08-30 Bio-Rad Laboratories, Inc. Composition utile pour le diagnostic et le traitement de l'infection par le HIV-I
WO1992022572A1 (fr) * 1991-06-13 1992-12-23 Replico Medical Ab Nouveaux peptides gag et env du vih-1, diagnostic
WO2004084940A1 (fr) * 2003-03-26 2004-10-07 Cytos Biotechnology Ag Encapsulation d'oligonucleotides immunostimulateurs dans des particules pseudovirales, procedes de preparation et utilisations
EP1466924A1 (fr) * 2003-04-11 2004-10-13 Institut Pasteur Vaccins de peptide synthétiques pour HIV: l'épitope de CBD comme immunogen efficace pour obtenir des anticorps neutralisants contre VIH
WO2006027468A2 (fr) * 2004-08-27 2006-03-16 Commissariat A L'energie Atomique Epitopes t cd4+ du vih restreints a hla-dp4 et leurs applications

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007616A1 (fr) * 1986-06-12 1987-12-17 Biogen N.V. Peptides impliques dans la pathogenese d'une infection du type hiv
EP0330359A2 (fr) * 1988-02-25 1989-08-30 Bio-Rad Laboratories, Inc. Composition utile pour le diagnostic et le traitement de l'infection par le HIV-I
WO1992022572A1 (fr) * 1991-06-13 1992-12-23 Replico Medical Ab Nouveaux peptides gag et env du vih-1, diagnostic
WO2004084940A1 (fr) * 2003-03-26 2004-10-07 Cytos Biotechnology Ag Encapsulation d'oligonucleotides immunostimulateurs dans des particules pseudovirales, procedes de preparation et utilisations
EP1466924A1 (fr) * 2003-04-11 2004-10-13 Institut Pasteur Vaccins de peptide synthétiques pour HIV: l'épitope de CBD comme immunogen efficace pour obtenir des anticorps neutralisants contre VIH
WO2006027468A2 (fr) * 2004-08-27 2006-03-16 Commissariat A L'energie Atomique Epitopes t cd4+ du vih restreints a hla-dp4 et leurs applications

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAFFAR O K ET AL: "HIV-SPECIFIC HUMORAL AND CELLULAR IMMUNITY IN RABBITS VACCINATED WITH RECOMBINANT HUMAN IMMUNODEFICIENCY VIRUS-LIKE GAG-ENV PARTICLES", VIROLOGY, vol. 183, no. 2, 1991, pages 487 - 495, XP002412044, ISSN: 0042-6822 *
LUO L ET AL: "Induction of V3-specific cytotoxic T lymphocytes responses by HIV gag particles carrying multiple immunodominant V3 epitopes of gp120", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 240, no. 2, 20 January 1998 (1998-01-20), pages 316 - 325, XP002291384, ISSN: 0042-6822 *
TOBIN G J ET AL: "Chimeric HIV-1 Virus-like Particles Containing gp120 Epitopes as a Result of a Ribosomal Frameshift Elicit Gag- and SU-Specific Murine Cytotoxic T-Lymphocyte Activities", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 236, no. 2, 29 September 1997 (1997-09-29), pages 307 - 315, XP004452082, ISSN: 0042-6822 *

Also Published As

Publication number Publication date
WO2007039458A2 (fr) 2007-04-12

Similar Documents

Publication Publication Date Title
WO2009080823A3 (fr) Conjugués du ngf et leurs utilisations
WO2006097530A3 (fr) Conjugues d'allergene du chat et utilisations associees
WO2006045796A3 (fr) Systemes d'antigenes de polypeptides inhibiteurs gastriques et utilisations
WO2004007538A3 (fr) Reseaux d'antigenes moleculaires
MX2007003171A (es) Particulas tipo virus que comprenden una proteina de fusion de la proteina de cubierta de ap205 y un polipeptido antigenico.
WO2002056905A3 (fr) Jeu ordonne d'echantillons d'antigenes moleculaires
WO2007095318A3 (fr) antigenes de la grippe, compositions de vaccins et procedes associes
WO2006037787A3 (fr) Conjugues vlp-antigene et leur utilisation comme vaccins
WO2006063974A3 (fr) Jeux ordonnes d'antigenes il-15 et leurs utilisations
WO2010010466A3 (fr) Anticorps neutralisant anti-virus influenza a et leurs utilisations
WO2004009124A3 (fr) Conjugues de porteurs de ghrelin
ATE489969T1 (de) Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
WO2009018500A8 (fr) Conjugué d'acide nucléique de polypeptide destiné à l'immunoprophylaxie ou à l'immunothérapie des troubles néoplasiques ou infectieux
HK1068355A1 (en) Antigen arrays presenting il-5, il-13 or eotaxin for treatment of allergic eosinophilic diseases
WO2003039225A3 (fr) Ensemble ordonne d'antigenes destines au traitement de maladies osseuses
WO2007039458A3 (fr) Conjugues peptidiques du vih et leurs utilisations
WO2005068639A3 (fr) Conjugues a base de ghreline et d'un vehicule
WO2005120558A3 (fr) Procede pour la fabrication de compositions comportant des proteines de choc thermique ou de l'alpha-2-macroglobuline pour le traitement du cancer et de maladie infectieuse
WO2006027300A3 (fr) Conjugues vecteurs des peptides de gonadoliberine (gnrh)
WO2005117983A3 (fr) Conjugues entraineurs des peptides du tnf
WO2003059386A3 (fr) Conjuges-vecteurs de proteines prion
WO2007008093A3 (fr) Procede permettant de fabriquer un vaccin recombine contre la maladie hemorragique virale du lapin, vaccin et application d'un antigene recombine dans la fabrication du vaccin
MXPA04003901A (es) Disposiciones de antigenos para el tratamiento de enfermedades eosinofilicas alergicas.
WO2002034288A8 (fr) Vaccin
MX2007003954A (es) Conjugados de antigeno de particula tipo virus y su uso como vacunas.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06806784

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载